Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Low-dose Radiation
100%
Antigen Escape
100%
Sialyl Lewis X
85%
Tumor Cells
57%
Chimeric Antigen Receptor Therapy
42%
Tumor
28%
Solid Tumors
28%
B-cell Malignancies
14%
RNA-seq Analysis
14%
Standard of Care
14%
Pancreatic Cancer
14%
Antigen Expression
14%
Highly Sensitive
14%
Conditioning Regimen
14%
Transcriptional Signature
14%
Pancreatic Adenocarcinoma
14%
Tumor Antigen
14%
Chimeric Antigen Receptor T-cell Therapy
14%
Tumor Relapse
14%
Heterogeneous Tumors
14%
CD19
14%
T Cell Killing
14%
Immune Rejection
14%
Heterogeneous Solids
14%
Medicine and Dentistry
Low Drug Dose
100%
Chimeric Antigen Receptor T-Cell
100%
Neoplasm
66%
Tumor Cell
66%
Chimeric Antigen Receptor Immunotherapy
50%
Solid Malignant Neoplasm
33%
Conditioning
33%
Chimeric Antigen Receptor
33%
Malignant Neoplasm
16%
RNA Sequence
16%
B Cell
16%
Cancer
16%
Pancreas Cancer
16%
Antigen Expression
16%
Immunity
16%
Tumor Antigen
16%
Pancreas Adenocarcinoma
16%
Cell Killing
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Immunology and Microbiology
Low Drug Dose
100%
Chimeric Antigen Receptor T-Cell
100%
Chimeric Antigen Receptor
83%
Tumor Cell
66%
TNF related apoptosis inducing ligand
50%
Conditioning
33%
B Cell
16%
Antigen Expression
16%
RNA Sequence
16%
Tumor Antigen
16%
Immunity
16%
Cell Killing
16%
CD19
16%
Chimeric Antigen Receptor T-Cell Therapy
16%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Low Drug Dose
100%
Chimeric Antigen Receptor
100%
TRAIL
27%
Conditioning
18%
RNA Sequence
9%
B Cell
9%
Tumor Antigen
9%
Cell Killing
9%
Immunity
9%
Antigen Expression
9%
CD19
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chimeric Antigen Receptor
100%
Neoplasm
72%
Solid Malignant Neoplasm
18%
Malignant Neoplasm
9%
Pancreas Cancer
9%
Tumor Antigen
9%
RNA-Sequencing
9%
Pancreas Adenocarcinoma
9%